Glenmark also recalls Ranitidine tablets from US markets


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ glenmark
Now Glenmark recalls Ranitidine tablets from US market

Pharma major, Glenmark Pharmaceutical, said it is  recalling all unexpired lots of its ranitidine tablets, from the US market.

The tablets are being recalled because of the presence or potential presence of N-nitrosodimethylamine (NDMA) levels above the acceptable daily intake levels established by the United States Food and Drug Administration (US FDA), as per the company’s announcement posted on the website of the US health regulator.

NDMA is classified as a probable human carcinogen (a substance that could cause cancer). It is a known environmental contaminant typically found in water and foods, including meats, dairy products and vegetables, it said.

The company said it has not received any reports of adverse events that have been confirmed to be directly related to this recall.

“Glenmark will continue to fully cooperate with the FDA as the agency evaluates ranitidine products for the presence of NDMA above established limits and formulates guidance for ranitidine manufacturers,” the announcement said.

“As a further precautionary measure, Glenmark ceased distribution of its ranitidine products in the United States while it continues its efforts to test and investigate in cooperation with the FDA,” it added.

The affected ranitidine tablets were distributed directly to wholesalers, distributors, retailers and repackagers nationwide.

Glenmark is notifying its direct customers by mailing a recall notification letter and is arranging for return of all recalled products. Anyone with an existing inventory of the product should quarantine the recalled lot immediately, it added.

“Consumers who have ranitidine tablets, USP subject to this recall should immediately discontinue use and consult with their physician or healthcare provider about treatment options,” it said.

“Glenmark’s Ranitidine tablets 150 mg and 300 mg are manufactured at two approved manufacturing facilities. Of the 928 recalled lots of ranitidine tablets, USP, 16 lots were manufactured by Glenmark Pharmaceuticals Ltd, Goa, and 912 lots were manufactured by Strides Pharma Science Ltd, Puducherry,” it said.

Tags : #recall #glenmarkranitidine #usmarket #health #medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Smart Operating Rooms: The Future of Hospital OTNovember 21, 2026
Smartphone Diagnostics: Phones as Medical Screening ToolsNovember 21, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026